NASDAQ:STRO - Sutro Biopharma Stock Price, Forecast & News

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma Inc (NASDAQ:STRO) posted its quarterly earnings data on Friday, November, 8th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.09. The business had revenue of $12.28 million for the quarter, compared to the consensus estimate of $8.88 million. View Sutro Biopharma's Earnings History.

Sutro Biopharma is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Sutro Biopharma.

7 brokerages have issued twelve-month price objectives for Sutro Biopharma's stock. Their forecasts range from $16.00 to $22.00. On average, they expect Sutro Biopharma's stock price to reach $19.17 in the next year. This suggests a possible upside of 71.0% from the stock's current price. View Analyst Price Targets for Sutro Biopharma.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma.

News headlines about STRO stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sutro Biopharma earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sutro Biopharma.

Sutro Biopharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 52,600 shares, an increase of 16.4% from the January 15th total of 45,200 shares. Based on an average daily volume of 60,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.6% of the company's shares are sold short. View Sutro Biopharma's Current Options Chain.

Some companies that are related to Sutro Biopharma include BAVARIAN NORDIC/S (BVNRY), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Sangamo Therapeutics (SGMO), DBV TECHNOLOGIE/S (DBVT), Vericel (VCEL), Proteon Therapeutics (PRTO), Atara Biotherapeutics (ATRA), Cellectis (CLLS), Avrobio (AVRO), Oyster Point Pharma (OYST), GENFIT S A/ADR (GNFT), MeiraGTx (MGTX) and Rubius Therapeutics (RUBY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Momo (MOMO), Sorrento Therapeutics (SRNE), Vaxart (VXRT), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Fortress Biotech (FBIO) and Inovio Pharmaceuticals (INO).

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (5.39%), BVF Inc. IL (1.50%), Driehaus Capital Management LLC (1.22%), State Street Corp (0.73%), FMR LLC (0.69%) and Granite Point Capital Management L.P. (0.43%). Company insiders that own Sutro Biopharma stock include Daniel H Petree, Merck & Co, Inc and Trevor Hallam. View Institutional Ownership Trends for Sutro Biopharma.

STRO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Creative Planning and Victory Capital Management Inc.. View Insider Buying and Selling for Sutro Biopharma.

STRO stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Granite Point Capital Management L.P., Victory Capital Management Inc., Jacobs Levy Equity Management Inc., Janus Henderson Group PLC, Spark Investment Management LLC, Acadian Asset Management LLC and Oxford Asset Management LLP. View Insider Buying and Selling for Sutro Biopharma.

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STRO stock can currently be purchased for approximately $11.21.

Sutro Biopharma has a market capitalization of $258.84 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.View Additional Information About Sutro Biopharma.

The official website for Sutro Biopharma is http://www.sutrobio.com/.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.